95%Confidence
0Views
FDASource
2026-04-09Date
Summary
The third Octreotide Acetate recall (30mg) from Teva confirms a widespread quality breakdown at Pharmathen International, severely impacting Teva's entire product line for this drug. This pattern suggests deep-rooted quality system deficiencies that could lead to prolonged market shortages and legal liabilities.
Actionable: Consider short-term impacts on Teva's stock and long-term quality assurance overhauls needed.
AI Confidence: 95%
Data Points
firmTeva Pharmaceuticals USA, Inc
classificationClass II
statusOngoing
distributionNationwide in the USA
productOctreotide Acetate for Injectable Suspension, for gluteal intramuscular use, 30 mg, Single-dose 8 mL vial, Rx only, Manufactured in Greece BY: Pharmat
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now